Spot Trading’s TherapeuticsMD TXMD Stock Holding History

Spot Trading’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-600	Closed	-$204K	–	3181
2016 Q3	$204K	Hold	600	–	–	﹤0.01%	2076
2016 Q2	$255K	Buy	+600	New	+$247K	﹤0.01%	2055

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spot Trading's TXMD Position: Q1 2016 in Review

Spot Trading sold out of TherapeuticsMD (TXMD) in Q1 2016, closing a stake of 256 shares — an estimated $133K sold.

Spot Trading first reported a position in TXMD in Q4 2015 and held it in 1 quarter. The position peaked at $133K in Q4 2015. 128 funds tracked by Wall St. Rank hold TXMD as of Q1 2016.

Spot Trading reported no remaining TherapeuticsMD position as of Q1 2016 after selling out during the quarter.
Spot Trading sold 256 TherapeuticsMD shares in Q1 2016, an estimated $133K.
Spot Trading first reported a position in TherapeuticsMD in Q4 2015 and held it in 1 quarter.
Spot Trading's TherapeuticsMD position peaked at $133K in Q4 2015.
128 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2016.

Based on Spot Trading's 13F filing for Q1 2016, filed 10 May 2016.